Solriamfetol and CBT-I in Patients With Insomnia Disorder

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
University of Pennsylvania
Study ID
NCT05838430
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
25 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Solriamfetol 75 MG — DRUG
    Solriamfetol (trade name Sunosi), is a norepinephrine-dopamine reuptake inhibitor available in 75mg and 150mg tablets for oral administration during the day. Solriamfetol's primary indication is to treat excessive daytime sleepiness (EDS) in patients diagnosed with obstructive sleep apnea or Narcolepsy. It binds to the dopamine and the norepinephrine transporters with affinities (Ki) of 14.2 μM and 3.7 μM, respectively),does not undergo significant metabolism in humans, and has a Tmax of \~2 hours (range 1.25-3.0 hours) and a T1/2 of \~7.1 hours.
  • Cognitive Behavioral Therapy for Insomnia (CBT-I) — BEHAVIORAL
    Treatment will be conducted via a HIPAA compliant video link (Zoom). Sessions 1-8 will follow our published protocol (published in 2005 by Springer). Each session will be conducted individually and have a singular focus per session. All sessions following the delivery of sleep restriction therapy \& stimulus control instructions (post Session 2) will include, as needed, management of non-adherence and/or time-in-bed titration.
  • Monitoring — OTHER
    No CBT-I will be administered, however, the tracking system used for CBT-I will be used for all subject conditions. This includes a sleep disorder symptoms screener, the administration of several questionnaires on a weekly basis, and the administration of daily sleep diaries online or via iPhone. Note: it is a common effect that regular monitoring of this type produces perceived clinical benefit.
  • Placebo — OTHER
    Placebo, identical in appearance to the active drug.

Study Details

Medication is FDA approved. The objective of this project is to test the efficacy of solriamfetol for treating insomnia (alone and in combination with Cognitive Behavioral Therapy for Insomnia \[CBT-I\]). Ultimately, this study will test whether wake extension (regardless of how it is achieved) will consolidate sleep and improve sleep continuity.

Key Dates

Start date
Jul 31, 2023
Status verified
May 2026
Primary completion
Jan 31, 2026
Completion
Apr 30, 2026

Study Design

Enrollment
115 participants (actual)
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Solriamfetol+ CBT-I
  • Experimental: Solriamfetol Only
  • Active Comparator: Placebo + CBT-I
  • Placebo Comparator: Placebo Only

Primary Outcome Measure

Sleep Continuity [ Time Frame: End of Treatment (12 Weeks) ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Pennsylvania, Behavioral Sleep Medicine ProgramPhiladelphiaPennsylvania19104-

Find similar trials in Philadelphia, PA

By condition

Related Studies